These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 19890244)

  • 1. Saxagliptin (Onglyza) for type 2 diabetes.
    Med Lett Drugs Ther; 2009 Nov; 51(1324):85-6. PubMed ID: 19890244
    [No Abstract]   [Full Text] [Related]  

  • 2. Saxagliptin + metformin. Mostly disadvantages.
    Prescrire Int; 2013 Feb; 22(135):40. PubMed ID: 23444500
    [No Abstract]   [Full Text] [Related]  

  • 3. Dapagliflozin/saxagliptin (Qtern) for type 2 diabetes.
    Med Lett Drugs Ther; 2018 Mar; 60(1543):55-56. PubMed ID: 29635266
    [No Abstract]   [Full Text] [Related]  

  • 4. Cost-effectiveness of saxagliptin (Onglyza®) in type 2 diabetes in Sweden.
    Granström O; Bergenheim K; McEwan P; Sennfält K; Henriksson M
    Prim Care Diabetes; 2012 Jul; 6(2):127-36. PubMed ID: 22001114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes.
    Rosenstock J; Sankoh S; List JF
    Diabetes Obes Metab; 2008 May; 10(5):376-86. PubMed ID: 18355324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment.
    Scheen AJ
    Expert Opin Drug Metab Toxicol; 2012 Mar; 8(3):383-94. PubMed ID: 22313172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in hemodialysis patients with diabetic nephropathy: A randomized open-label prospective trial.
    Abe M; Higuchi T; Moriuchi M; Okamura M; Tei R; Nagura C; Takashima H; Kikuchi F; Tomita H; Okada K
    Diabetes Res Clin Pract; 2016 Jun; 116():244-52. PubMed ID: 27321342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview of saxagliptin efficacy and safety in patients with type 2 diabetes and cardiovascular disease or risk factors for cardiovascular disease.
    Toth PP
    Vasc Health Risk Manag; 2015; 11():9-23. PubMed ID: 25565858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reaching HbA1c goals with saxagliptin in combination with other oral antidiabetic drugs.
    LaSalle JR
    Postgrad Med; 2010 Jan; 122(1):144-52. PubMed ID: 20107298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Saxagliptin: a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus.
    Neumiller JJ; Campbell RK
    Am J Health Syst Pharm; 2010 Sep; 67(18):1515-25. PubMed ID: 20811029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of Saxagliptin in the Treatment of Type 2 Diabetes: Review of Efficacy and Safety.
    Jain R
    Adv Ther; 2015 Nov; 32(11):1065-84. PubMed ID: 26578430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A post hoc analysis of saxagliptin efficacy and safety in patients with type 2 diabetes stratified by UKPDS 10-year cardiovascular risk score.
    Bonora E; Bryzinski B; Hirshberg B; Cook W
    Nutr Metab Cardiovasc Dis; 2016 May; 26(5):374-9. PubMed ID: 27033025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of saxagliptin for the treatment of type 2 diabetes mellitus.
    Orime K; Terauchi Y
    Expert Opin Pharmacother; 2020 Dec; 21(17):2101-2114. PubMed ID: 32990096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes.
    Karyekar C; Donovan M; Allen E; Fleming D; Ravichandran S; Chen R
    Postgrad Med; 2011 Jul; 123(4):63-70. PubMed ID: 21680990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus.
    Hollander PL; Li J; Frederich R; Allen E; Chen R;
    Diab Vasc Dis Res; 2011 Apr; 8(2):125-35. PubMed ID: 21562064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Saxagliptin and tuberculosis.
    Prescrire Int; 2013 Jan; 22(134):17. PubMed ID: 23383408
    [No Abstract]   [Full Text] [Related]  

  • 17. No benefit of saxagliptin on cardiovascular outcomes in type 2 diabetes mellitus: potential explanations.
    Jialal I; Dhindsa S
    Metab Syndr Relat Disord; 2014 Apr; 12(3):157-8. PubMed ID: 24520851
    [No Abstract]   [Full Text] [Related]  

  • 18. Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks.
    Chacra AR; Tan GH; Ravichandran S; List J; Chen R;
    Diab Vasc Dis Res; 2011 Apr; 8(2):150-9. PubMed ID: 21562067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic, pharmacodynamic and clinical evaluation of saxagliptin in type 2 diabetes.
    Anderson R; Hayes J; Stephens JW
    Expert Opin Drug Metab Toxicol; 2016; 12(4):467-73. PubMed ID: 26878666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus.
    Scheen AJ; Charpentier G; Ostgren CJ; Hellqvist A; Gause-Nilsson I
    Diabetes Metab Res Rev; 2010 Oct; 26(7):540-9. PubMed ID: 20824678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.